Friday 16 October 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.99
0.00
0.00%
Follow LRMR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.19 | 8.02 | 9.49 | 11.28 | 11.28 | 8.16 | 8.16 | 10.89 | 10.89 | 0.81 |
Net Debt/EBITDA |
0.79 | 1.91 | 2.00 | 3.20 | 3.13 | 1.40 | 1.29 | 2.17 | 2.03 | 0.04 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 3.79% | 0.00% | 6.87% | 0.00% | 5.73% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.08 | 0.00 | 0.07 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.68 | 0.88 | 0.91 | 0.78 | 0.78 | 0.83 | 0.83 | 0.99 | 0.99 | 0.98 |
Capex/Depreciation |
0.07 | 0.10 | 0.11 | 0.22 | 0.00 | (1.07) | 0.00 | (0.38) | 0.00 | (1.06) |
Interest Coverage |
— | — | — | — | — | — | — | — | — | (13.14) |
| (132.59%) | (63.58%) | (38.36%) | (40.33%) | 0.00% | (65.72%) | 0.00% | (95.47%) | 0.00% | (49.97%) | |
| (95.75%) | (54.43%) | (33.24%) | (34.48%) | 0.00% | (55.23%) | 0.00% | (77.32%) | 0.00% | (36.44%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(212.81%) | (46.91%) | (45.42%) | (31.89%) | (31.09%) | (78.62%) | (74.67%) | (47.20%) | (45.22%) | 2,655.80% |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — | 0.00% | — | 0.00% |
Free Cash Flow per Share |
(1.55) | (1.16) | (0.77) | (1.07) | (1.07) | (2.47) | (2.45) | (3.56) | (3.55) | (3.74) |
Cash per Share |
1.88 | 2.99 | 1.98 | 4.60 | 4.60 | 4.08 | 4.08 | 7.80 | 7.80 | 0.17 |
Shareholders Equity per Share |
1.07 | 2.80 | 1.86 | 4.31 | 4.31 | 3.75 | 3.75 | 7.55 | 7.55 | (0.11) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.07 | 2.80 | 1.86 | 4.31 | 4.31 | 3.75 | 3.75 | 7.55 | 7.55 | (0.11) |
Free Cash Flow |
(113.29) | (71.27) | (33.62) | (27.67) | (27.57) | (42.44) | (42.10) | (42.26) | (42.21) | (22.78) |
Working Capital |
77.23 | 170.95 | 80.67 | 110.03 | 110.03 | 63.36 | 63.36 | 88.96 | 88.96 | (1.14) |
Capital Expenditures |
(0.09) | (0.51) | (0.16) | (0.10) | (0.10) | (0.33) | (0.33) | (0.06) | (0.06) | (0.08) |
Net Current Asset Value |
74.27 | 166.89 | 75.96 | 105.24 | 105.24 | 57.95 | 57.95 | 82.96 | 82.96 | (1.14) |
| Other line items | ||||||||||
Quick Ratio |
2.11 | 7.53 | 9.13 | 11.06 | 11.06 | 7.92 | 7.95 | 10.30 | 10.31 | 0.17 |
Depreciation/Fixed assets |
(2.17) | (5.60) | (2.24) | (0.55) | 0.07 | 0.30 | 0.07 | 0.16 | 0.03 | 0.28 |
Cash ROIC |
(52.71%) | (20.06%) | (19.95%) | (12.07%) | (11.78%) | (31.55%) | (30.09%) | (23.18%) | (22.41%) | (7,232.38%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.55) | (1.16) | (0.76) | (1.07) | (1.07) | (2.45) | (2.45) | (3.55) | (3.55) | (3.73) |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | (0.01) | 0.00 | (0.01) |
Average Receivables |
— | — | — | — | — | — | 0.12 | — | 0.14 | 0.37 |
Average Payables |
3.82 | 1.85 | 1.48 | 1.67 | 1.67 | 2.15 | 2.15 | 3.09 | 3.09 | 3.56 |
Average Assets |
173.03 | 148.08 | 111.17 | 102.54 | 102.54 | 91.68 | 91.68 | 54.94 | 54.94 | 63.48 |
Average Common Equity |
124.95 | 126.77 | 96.31 | 87.66 | 87.66 | 77.05 | 77.05 | 44.50 | 44.50 | 46.29 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | 0.00 |
Columns are period end dates